𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study

✍ Scribed by M.-R. Taskinen; J. Rosenstock; I. Tamminen; R. Kubiak; S. Patel; K. A. Dugi; H.-J. Woerle

Book ID
109045081
Publisher
John Wiley and Sons
Year
2010
Tongue
English
Weight
797 KB
Volume
13
Category
Article
ISSN
1462-8902

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

A double-blind, placebo-controlled evalu
A double-blind, placebo-controlled evaluation of the efficacy and safety of loreclezole as add-on therapy in patients with uncontrolled partial seizures
✍ T Rentmeester; A Janssen; J Hulsman; F Scholtes; B van der Kleij; J Overweg; J M πŸ“‚ Article πŸ“… 1991 πŸ› Elsevier Science 🌐 English βš– 655 KB

Sixty-two patients with uncontrolled partial seizures participated in a 12-week, double-blind, placebo-controlled add-on-trial. Thirty-two patients received loreclezole and 30 a placebo as add-on therapy. Loreclezole was targeted at a plasma level of 1-2 mg/l. In spite of an antiepileptic therapy, u

A randomized, double-blind, placebo-cont
A randomized, double-blind, placebo-controlled trial of safinamide as add-on therapy in early Parkinson's disease patients
✍ Fabrizio Stocchi; Rupam Borgohain; Marco Onofrj; Anthony H.V. Schapira; Mohit Bh πŸ“‚ Article πŸ“… 2011 πŸ› John Wiley and Sons 🌐 English βš– 446 KB πŸ‘ 2 views

## Abstract Safinamide is an α‐aminoamide with both dopaminergic and nondopaminergic mechanisms of action evaluated as an add‐on to dopamine agonist (DA) therapy in early‐stage PD. In this 24‐week, double‐blind study, patients with early PD receiving a stable dose of a single DA were randomized to